TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. healthy individual with normal blood chemistries and platelet counts who has not been diagnosed with diabetes, cardiovascular illness, or other chronic diseases~2. 50 to 70 years of age~3. body mass index between 25 and 39.9 kg/m2~4. for females, post-menopausal (i.e., no menstrual cycle for \> one year).~Exclusion Criteria:~1. Potential participants will be excluded if their scores on the dietary restraint, disinhibition, and perceived hunger scales of the Eating Inventory are high (\>14)~2. Participants who report smoking cigarettes will be excluded because of the effects of nicotine upon taste and appetite~3. Participants who have a diagnosable eating disorder will also be excluded since intentional restriction of eating and binge eating/overeating could increase the variability of the data~4. Participants will be excluded if they are taking anti-depressant medications, anti-psychotic medications, or any medications, botanicals, or other products that may potentially influence appetite, hunger, and/or satiety~5. Participants will be excluded if they report alcohol or substance abuse within 6 months or consumption of \>14 alcohol drinks/week~6. Participants will also be excluded if they report any allergies to the foods used in the study~7. Volunteers will also be ineligible if they have significant medical conditions (e.g., history or clinical manifestation of cardiovascular disease, diabetes, cholelithiasis, liver or renal disease, or cancer)~   * abnormal laboratory markers (e.g., renal or liver abnormalities, elevated potassium levels or hemoglobin and hematocrit below the lower limit of normal)~  * psychiatric or behavioral problems (e.g., eating disorders or a history of drug and alcohol abuse)~  * concomitant medications (e.g., steroids)~8. Volunteers will be screened out if they are unwilling or unable to adhere to different supplement regimens over an eight month period.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- microcrystalline cellulose (Type: PLACEBO_COMPARATOR): None
- Hydroxycitric acid (Type: ACTIVE_COMPARATOR): 2800 mg divided in three doses per day
- Hydroxycitric Acid (Type: ACTIVE_COMPARATOR): 5400 mg divided into three doses per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. patients who are presenting for ACL reconstruction~2. candidates for peripheral nerve blocks patients~3. ASA 1-3~Exclusion Criteria:~1. Patient refusal~2. ASA Classification of 4 or higher~3. Pre-existing neuropathy in the femoral or sciatic distribution~4. Coagulopathy~5. Infection at the site~6. Non-English speaking or non-reading patients~7. Chronic opioid use (\>3months)~8. Pregnancy~9. Any other contra-indication to regional anesthesia~10. Failed femoral nerve block~11. Sciatic nerve block placed due to severe pain not managed by intravenous and oral agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug (Type: ACTIVE_COMPARATOR): Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
- Preservative free normal saline (Type: SHAM_COMPARATOR): Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients, ≥ 18 years of age~* Active rheumatoid arthritis~* Inadequate treatment with any DMARD other than methotrexate~Exclusion criteria:~* Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis~* Concurrent treatment with any DMARD other than methotrexate~* Previous treatment with any cell-depleting therapies~* Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo:~* on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~* on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)
- Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
- Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
- Ocrelizumab 200mg/ Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
- Ocrelizumab 200mg/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
- Ocrelizumab 400mg/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
- Placebo/ Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
- Placebo/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin in Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.~Main criteria are listed hereafter:~Inclusion Criteria:~* ECOG: 0-2~* Histological proved rectal adenocarcinoma~* No chemotherapy treatment on the previous 6 months before inclusion.~* No previous pelvic radiotherapy treatment~Exclusion Criteria:~* Important Biological abnormality (renal, hepatic and/or hematological)~* Intestinal occlusion or subocclusion~* Peripheral neuropathy~* Pregnant or breast-feeding women. Potential child-bearing women with a positive pregnancy test.~* Participation in other trials on the previous 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repeated Educational Intervention for the Prevention of Diabetic Foot Ulcers in High-risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Either diabetic neuropathy or previous foot ulcer~Exclusion Criteria:~* Arteriopathy of lower limbs, with ABI\<0.8 or needing revascularization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Repeated educational intervention (Type: EXPERIMENTAL): Repetition every 6 months of a group educational session
- Control group (Type: ACTIVE_COMPARATOR): Initial single group educational session, with no repetition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male and female patients, aged 18 and above.~* ApoA-I \< 70 mg/dL~* Symptomatic or asymptomatic cardiovascular disease~* Diagnosis of genetically confirmed HDL-c deficiency due to defects in genes coding for ABCA1 and/or ApoA-1~* Stable doses of lipid lowering therapies for at least 6 weeks prior to baseline procedures~Main Exclusion Criteria:~* Females of childbearing potential~* Patients with LCAT mutations~* Patients who experienced recent cardiovascular or cerebrovascular events~* Hypertriglyceridemia (\>500 mg/dL)~* Severe anemia (Hgb \< 10 g/dL)~* Uncontrolled diabetes (HbA1c \>10%)~* Congestive heart failure (NYHA class II or higher)~* Contraindication for MRI scanning (e.g., implanted metal objects, claustrophobia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CER-001 (Type: EXPERIMENTAL): CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
- Placebo (Type: PLACEBO_COMPARATOR): Saline infusion; 9 weekly infusions followed by 20 biweekly infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult emmetropic patient~* Without complete posterior vitreus detachment in both eyes before having surgery.~Exclusion Criteria:~* Diabetic retinopathy~* Ophthalmological treatment in progress~* History of ophthalmological surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cataract surgery (Type: OTHER): Patient acts as his own control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women of childbearing potential must agree to use an acceptable method of birth control~* clinical diagnosis of community acquired bacterial pneumonia (CABP)~* PORT score of II or greater~* able to generate an adequate sputum specimen~* chest x-ray showing presence of new infiltrates in a lobar or multilobar distribution characteristic of bacterial pneumonia~Exclusion Criteria:~* history of tendon damage/disorders due to quinolone therapy~* uncorrected hypokalemia~* history of myasthenia gravis~* intubated at the time of consent OR subject is a candidate for enrollment into the open-label S. aureus arm and has been intubated greater than 12 hours prior to randomization~* mild CABP with a PORT score of less than II~* viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis~* pneumonia suspected to be secondary to aspiration~* primary, solitary lung abscess~* healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia~* known bronchial obstruction or a history of postobstructive pneumonia.~* primary lung cancer or another malignancy metastatic to the lungs~* cystic fibrosis, known or suspected Pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis~* infection that necessitates the use of a concomitant antibacterial agent in addition to study medication~* systemic antibiotics within the last 96 hours before randomization, with exceptions~* hospitalized for greater than 72 hours for any reason 30 days before randomization (excluding the 24 hour period before enrollment).~* history of a serious hypersensitivity reaction to any quinolone including moxifloxacin.~* female and pregnant, breastfeeding, or may be pregnant.~Other protocol-specific eligibility criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-32729463 (Type: EXPERIMENTAL): None
- moxifloxacin (Type: ACTIVE_COMPARATOR): None
- JNJ-32729463 Open-Label (Type: EXPERIMENTAL): subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: INBONE™ Total Ankle Prosthesis With Long Talar Stem

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has sufficient soft tissue and muscle strength to support stable, anatomic positioning and motion of arthroplasty components as determined by the investigator~2. Subject must have sufficient skin for wound coverage.~3. Subject demonstrates subtalar joint insufficiency as defined by any of the following:~(1)range of motion \<50 percent of the contralateral, non-diseased side (2)pain during physical examination of the subtalar joint (3)fusion~AND~Subject demonstrates tibio-talar joint insufficiency as defined by any of the following:~1. end stage arthritis as determined by the investigator on plain radiographs~2. pain during physical examination of the tibio-talar joint~3. fusion~4. non-union~5. failed Total Ankle Replacement 4.Subject has Body Mass Index (BMI) \< 40 5.Subject has sufficient calcaneal bone stock as determined by the investigator 6.Subject is able to or capable of providing consent to participate in the clinical investigation and has medical insurance to cover costs associated with their medical care or is willing to assume personal responsibility for costs 7.Subject agrees to comply with this protocol, including participating in required follow-up visits at the investigations site and completing study questionnaires~Exclusion Criteria:~1. Subject is skeletally immature and under 21 years of age~2. Subject has experienced local or systemic infection within the past twelve months~3. Subject has symptomatic ankle disease or has been treated operatively on the contralateral side~4. Subject has vascular and kidney insufficiencies~5. Subject is suspected to have neuropathy of the foot or ankle~6. Subject has impaired vascular circulation in the affected limb~7. Subject has skin condition that may impair wound healing~8. Subject has known allergy to cobalt, chromium, molybdenum, titanium, aluminum, vanadium, or nickel~9. Subjects on long term medications which may compromise bone stock (e.g. long term steroids, NSAIDS, etc., physicians discretion~10. Subject is unwilling or unable to comply with a rehabilitation program~11. Subject is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser~12. Subject is currently participating in any investigational study not related to this study's preoperative and postoperative care.~13. Subject has rheumatoid arthritis (RA)~14. Subject has been diagnosed with osteoporosis as defined as a DXA t-score \>-2.5.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arthritic and injured ankles (Type: EXPERIMENTAL): InBone TAA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* RDI \> 15~* Symptomatic Heart failure~* Oxygen saturation \< 88% during apnea~* Not currently be on nocturnal oxygen therapy, CPAP, or other PAP therapy~Exclusion Criteria:~* Hypoxemia requiring oxygen supplementation~* serum creatinine \> 2.5 or on chronic dialysis~* blood pressure \> 160~* pregnant~* chronic physical disability that would prevent subjects from participating in any aspect of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasal oxygen (Type: ACTIVE_COMPARATOR): Nocturnal nasal oxygen
- No nasal oxygen (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Major patient who has been informed about the study;~* Allografted patient with molecular or clinical relapse.~Exclusion Criteria:~* Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;~* Not able to understand and complete surveys.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hematological patients who underwent allograft (Type: None): Patients who underwent allograft and then relapsed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lubricant Investigation in Men to Inhibit Transmission of HPV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18 or older,~* Men living in Montreal and plan to remain in the city for the next 12 months,~* Men who have had receptive anal sex with one or more men during the previous 3 months and intend to continue being sexually active for the duration of their involvement in the study, irrespective of whether their sexual partner will change,~* Men planning on having receptive anal sex with two or more men, but less than 50 DIFFERENT partners per year~* Men who understands French or English,~* Men willing to follow study instructions and comply with follow-ups for 12 months.~Exclusion Criteria:~* Men must not be receiving treatment for anal or perianal condylomas or anal intraepithelial neoplasia lesions during the trial,~* Men must not have a known allergy or hypersensitivity to any of the ingredients in either gels.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Carrageenan-based gel (Type: EXPERIMENTAL): The intervention to be administered is:~* a commercially available gel that contains carrageenan.~* water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~* also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water.
- Control gel (Type: PLACEBO_COMPARATOR): The intervention to be administered is:~* a commercially available gel that does not contain carrageenan.~* water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~* also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues